Maternal Bisphenol a Levels in Patients Diagnosed with Preeclampsia: A Case-Control Study

Abstract

Objective: This study aims to assess Bisphenol-A levels in serum samples from preeclampsia patients and determine potential distinctions by comparing them against samples from healthy pregnant women Material-Methods: This single-center prospective case-control study aimed to investigate the potential differences in serum Bisphenol-A (BPA) levels between pregnant patients diagnosed with preeclampsia and healthy pregnant women. The study encompassed two distinct groups: the study group consisted of 30 pregnant patients diagnosed with preeclampsia, while the control group included 30 healthy pregnant women matched in terms of gestational weeks and demographic characteristics, maintaining a 1:1 ratio. Serum samples were subjected to analysis using a BPA ELISA kit Results: The study encompassed a total of 60 patients, who were categorized into two groups: preeclampsia (n=30) and control (n=30). Upon comparison of the BPA values between the two groups, no statistically significant difference was detected (p=0.579). Conclusion: Clear-cut scientific evidence establishing a conclusive causal link between BPA and preeclampsia is still lacking. Further research is needed in this area

Keywords

• Bisphenol A
• Preeclampsia
• Pregnancy

References

1. 1. Jung E, Romero R, Yeo L ve ark. The etiology of preeclampsia. Am J Obstet Gynecol. 2022; 226(2s):S844-s66.
2. 2. Erçal T. Şiddetli preeklampsi ve eklampsi: hastane öncesi tani ve yönetimde güncel yaklaşimlar. Hastane Öncesi Dergisi. 2019; 4(1):33-46.
3. 3. Cimmino I, Fiory F, Perruolo G ve ark. Potential Mechanisms of Bisphenol A (BPA) Contributing to Human Disease. Int J Mol Sci. 2020; 21(16).
4. 4. Vom Saal FS, Nagel SC, Coe BL et al. The estrogenic endocrine disrupting chemical bisphenol A (BPA) and obesity. Mol Cell Endocrinol. 2012; 354(1-2):74-84.
5. 5. Ehrlich S, Lambers D, Baccarelli A et al. Endocrine Disruptors: A Potential Risk Factor for Gestational Diabetes Mellitus. Am J Perinatol. 2016; 33(13):1313-18.
6. 6. den Braver-Sewradj SP, van Spronsen R, Hessel EVS. Substitution of bisphenol A: a review of the carcinogenicity, reproductive toxicity, and endocrine disruption potential of alternative substances. Crit Rev Toxicol. 2020; 50(2):128-47.
7. 7. Wang ZY, Lu J, Zhang YZ ve ark. Effect of Bisphenol A on invasion ability of human trophoblastic cell line BeWo. Int J Clin Exp Pathol. 2015; 8(11):14355-64.
8. 8. Zhang YF, Shan C, Wang Y et al. Cardiovascular toxicity and mechanism of bisphenol A and emerging risk of bisphenol S. Sci Total Environ. 2020; 723:137952.

9. 9. Arita Y, Park HJ, Cantillon A et al. Effect of bisphenol-A (BPA) on placental biomarkers for inflammation, neurodevelopment and oxidative stress. J Perinat Med. 2019; 47(7):741-49.
10. 10. D'Angelo S, Scafuro M, Meccariello R. BPA and Nutraceuticals, Simultaneous Effects on Endocrine Functions. Endocr Metab Immune Disord Drug Targets. 2019; 19(5):594-604.
11. 11. Wehbe Z, Nasser SA, El-Yazbi A ve ark. Estrogen and Bisphenol A in Hypertension. Curr Hypertens Rep. 2020; 22(3):23.
12. 12. Camara LR, Arbuckle TE, Trottier H et al. Associations between Maternal Exposure to Bisphenol A or Triclosan and Gestational Hypertension and Preeclampsia: The MIREC Study. Am J Perinatol. 2019; 36(11):1127-35.
13. 13. Dagdeviren G, Arslan B, Keles A et al. The evaluation of serum bisphenol A in patients with preeclampsia. J Obstet Gynaecol Res. 2023; 49(5):1322-27.
14. Leclerc F, Dubois MF, Aris A. Maternal, placental and fetal exposure to bisphenol A in women with and without preeclampsia. Hypertens Pregnancy. 2014; 33(3):341-48.